JP2023527819A - 細胞のゲノムを改変するためのマルチプレックスＣＲＩＳＰＲ／Ｃａｓ系 - Google Patents

細胞のゲノムを改変するためのマルチプレックスＣＲＩＳＰＲ／Ｃａｓ系 Download PDF

Info

Publication number
JP2023527819A
JP2023527819A JP2022572491A JP2022572491A JP2023527819A JP 2023527819 A JP2023527819 A JP 2023527819A JP 2022572491 A JP2022572491 A JP 2022572491A JP 2022572491 A JP2022572491 A JP 2022572491A JP 2023527819 A JP2023527819 A JP 2023527819A
Authority
JP
Japan
Prior art keywords
type
cas
cas3
cell
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572491A
Other languages
English (en)
Japanese (ja)
Inventor
デル ヘルム，エリック ヴァン
マルティネス，ヴァージニア
タコス，アダム
Original Assignee
エスエヌアイピーアール・バイオーム・アーペーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスエヌアイピーアール・バイオーム・アーペーエス filed Critical エスエヌアイピーアール・バイオーム・アーペーエス
Publication of JP2023527819A publication Critical patent/JP2023527819A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2022572491A 2020-05-27 2021-05-26 細胞のゲノムを改変するためのマルチプレックスＣＲＩＳＰＲ／Ｃａｓ系 Pending JP2023527819A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2007943.0 2020-05-27
GBGB2007943.0A GB202007943D0 (en) 2020-05-27 2020-05-27 Products & methods
PCT/EP2021/063954 WO2021239758A1 (fr) 2020-05-27 2021-05-26 Système crispr/cas multiplex pour modifier des génomes de cellules

Publications (1)

Publication Number Publication Date
JP2023527819A true JP2023527819A (ja) 2023-06-30

Family

ID=71406263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572491A Pending JP2023527819A (ja) 2020-05-27 2021-05-26 細胞のゲノムを改変するためのマルチプレックスＣＲＩＳＰＲ／Ｃａｓ系

Country Status (7)

Country Link
EP (1) EP4158021A1 (fr)
JP (1) JP2023527819A (fr)
CN (1) CN115552007A (fr)
CA (1) CA3171200A1 (fr)
FR (1) FR3110916A1 (fr)
GB (1) GB202007943D0 (fr)
WO (1) WO2021239758A1 (fr)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140189896A1 (en) 2012-12-12 2014-07-03 Feng Zhang Crispr-cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
JP7065564B2 (ja) * 2013-05-29 2022-05-12 セレクティス Ｃａｓ９ニッカーゼ活性を用いて正確なｄｎａ切断をもたらすための方法
SG10201913015XA (en) * 2013-07-10 2020-02-27 Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
EP3041498B1 (fr) 2013-09-05 2022-02-16 Massachusetts Institute of Technology Réglage de populations microbiennes à l'aide de nucléases programmables
WO2015066119A1 (fr) 2013-10-30 2015-05-07 North Carolina State University Compositions et méthodes liées à un système crispr-cas de type ii chez lactobacillus buchneri
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
EP3126503A1 (fr) 2014-04-03 2017-02-08 Massachusetts Institute Of Technology Procédés et compositions pour la production d'arn de guidage
SG11201701245QA (en) * 2014-08-27 2017-03-30 Caribou Biosciences Inc Methods for increasing cas9-mediated engineering efficiency
IL310108A (en) 2015-05-06 2024-03-01 Snipr Tech Ltd Changing bacterial populations and microbiota adaptation
GB2531454A (en) 2016-01-10 2016-04-20 Snipr Technologies Ltd Recombinogenic nucleic acid strands in situ
EA201792663A1 (ru) 2015-05-29 2018-04-30 Норт Каролина Стейт Юниверсити Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
EP3307872B1 (fr) 2015-06-15 2023-09-27 North Carolina State University Procédés et compositions permettant une délivrance efficace d'acides nucléiques et d'antimicrobiens à base d'arn
WO2016205623A1 (fr) 2015-06-17 2016-12-22 North Carolina State University Méthodes et compositions pour l'édition de génome dans des bactéries à l'aide de systèmes cas9-crispr
WO2017009399A1 (fr) 2015-07-13 2017-01-19 Institut Pasteur Amélioration des agents antimicrobiens spécifiques à une séquence par le blocage de la réparation de l'adn
WO2017058751A1 (fr) 2015-09-28 2017-04-06 North Carolina State University Méthodes et compositions pour agents antimicrobiens spécifiques d'une séquence
EP4089175A1 (fr) 2015-10-13 2022-11-16 Duke University Ingénierie génomique avec systèmes crispr de type i dans des cellules eucaryotes
US11542466B2 (en) 2015-12-22 2023-01-03 North Carolina State University Methods and compositions for delivery of CRISPR based antimicrobials
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US20190323038A1 (en) * 2016-06-17 2019-10-24 Montana State Univesity Bidirectional targeting for genome editing
EP3532850A1 (fr) 2016-10-28 2019-09-04 Massachusetts Institute Of Technology Bactériophages synthétiques et compositions bactériophages
EP3645716A2 (fr) 2017-06-25 2020-05-06 Snipr Technologies Limited Modification de populations microbiennes et modification de microbiote
GB201710126D0 (en) * 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
US20190160120A1 (en) 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
EP3740580A4 (fr) 2018-01-19 2021-10-20 Duke University Ingénierie génomique avec des systèmes crispr-cas dans des eucaryotes
US20210115475A1 (en) * 2018-01-30 2021-04-22 Editas Medicine, Inc. Systems and methods for modulating chromosomal rearrangements
EP4085923A1 (fr) 2018-03-25 2022-11-09 SNIPR Biome ApS. Traitement et prévention des infections microbiennes
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP3788152A4 (fr) * 2018-05-04 2022-03-09 Locus Biosciences, Inc. Procédés et compositions pour détruire une bactérie cible
EP3817556A4 (fr) 2018-05-25 2022-03-30 Locus Biosciences, Inc. Procédés et compositions pour détruire une bactérie cible
KR20210089629A (ko) 2018-06-05 2021-07-16 라이프에디트 테라퓨틱스, 인크. Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법
WO2020072254A1 (fr) 2018-10-01 2020-04-09 North Carolina State University Système crispr-cas de type i recombinant et ses utilisations pour tuer des cellules cibles
WO2020072253A1 (fr) 2018-10-01 2020-04-09 North Carolina State University Système crispr-cas de type i recombinant et ses utilisations pour le criblage de cellules variantes
EP3861120A4 (fr) 2018-10-01 2023-08-16 North Carolina State University Système crispr-cas de type i recombinant
WO2020072250A1 (fr) 2018-10-01 2020-04-09 North Carolina State University Système crispr-cas de type i recombinant et utilisations de ce dernbier pour la modification du génome et la modification de l'expression
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
GB201907733D0 (en) * 2019-05-31 2019-07-17 Governing Council Of The Univ Of Toronto Methods and compositions for multiplex gene editing
US20220411782A1 (en) * 2019-11-06 2022-12-29 Locus Biosciences, Inc. Phage compositions comprising crispr-cas systems and methods of use thereof

Also Published As

Publication number Publication date
FR3110916A1 (fr) 2021-12-03
GB202007943D0 (en) 2020-07-08
CA3171200A1 (fr) 2021-12-02
EP4158021A1 (fr) 2023-04-05
WO2021239758A1 (fr) 2021-12-02
CN115552007A (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
Gholizadeh et al. How CRISPR-Cas system could be used to combat antimicrobial resistance
JP7280905B2 (ja) Ｃｒｉｓｐｒｃｐｆ１の結晶構造
US20180140698A1 (en) Selectively altering microbiota for immune modulation
EP3080260B1 (fr) Systèmes crispr-cas et méthodes de modification de l'expression de produits géniques, informations structurales et enzymes cas modulaires inductibles
US20180193269A1 (en) NANO-LIPOSOME CARRIER COMPOSITION CONTAINING HYBRID OF Cas9 PROTEIN AND GUIDE RNA
JP2021507682A (ja) Ｒｎａ治療薬を含むエクソソーム
WO2014093479A1 (fr) Contrôle de la régulation génétique guidé par arn crispr (répétitions palindromiques groupées, courtes régulièrement espacées )
Bikard et al. Development of sequence-specific antimicrobials based on programmable CRISPR-Cas nucleases
CA3026055A1 (fr) Nouvelles enzymes crispr et systemes associes
JP7471289B2 (ja) 抗ｌｉｖ１免疫細胞癌療法
Liu et al. Viral nanoparticle-encapsidated enzyme and restructured DNA for cell delivery and gene expression
WO2023119201A2 (fr) Lymphocytes t génétiquement modifiés avec un proto-oncogène-b de lymphome de lignée de casitas interrompu (cblb) et leurs utilisations
Pizarro-Bauerle et al. Engineered bacteriophages for practical applications
KR20230003511A (ko) 안면견갑상완 근이영양증에 대한 crispr-억제
JP2022531185A (ja) 遺伝子改変ｔ細胞を標的化するｃｄ１９を使用するｂ細胞悪性病変の同種細胞療法
JP6425699B2 (ja) 細菌中の接合性プラスミドの低減方法
US20210347913A1 (en) Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (ptk7) and immune cells expressing such
JP2023527819A (ja) 細胞のゲノムを改変するためのマルチプレックスＣＲＩＳＰＲ／Ｃａｓ系
US20220233712A1 (en) Exosome comprising stabilized rna therapeutics
JP2023542410A (ja) 合成ウイルス
KR20220025757A (ko) 진핵 세포에 유전자 편집 시스템을 전달하기 위한 박테리아 플랫폼
JPH09512030A (ja) 選択マーカー遺伝子のない ｄｎａベクターを用いる遺伝子治療方法
WO2023025208A1 (fr) Procédé de modification de cellule
Lal et al. Curative Therapy of Sickle Cell Disease Using Gene Editing Technologies
WO2023111286A1 (fr) Procédés et compositions pour l'administration d'acides nucléiques